Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120)

Pyle, Stephen W.; Morein, Brør; Bess, Julian W.; Åkerblom, Lennart; Nara, Peter L.; Nigida, Stephen M.; Lerche, Nicholas W.; Robey, W G; Fischinger, Peter J.; Arthur, Larry O.

doi:10.1016/0264-410x(89)90164-3

Cited by 58 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of a suitable vaccine is hampered by the variability of the viral envelope protein gpl20 which induces neutralizing antibodies. Multiple injections in rhesus monkeys with iscoms containing gpl20 of HIV1 induced ten-fold higher neutralizing titres than comparable amounts of gpl20 with an alum adjuvant (Pyle et al, 1989). In mice, a 5-ug dose of these gpl20 iscoms induced two-fold higher titres when compared with a 5Oyg dose of gpl20 in complete Freunds' adjuvant.…”

Section: Retroviridaementioning

confidence: 94%

“…Quil A is a necessary constituent of the iscom structure. The size and morAntigen nature Name Mowatt et al, 1991a/b Lovgren et al, 1987Erturk et al, 1989Trudel et al, 1987, 1988Wahren et al, 1987Tsuda et al, 1991Morgan et al, 1988Howard et al, 1987Trudel et al, 1988Carlson et al, 1991De Vries et al, 1988aDe Vries et al, 1988bVisser et al, 1989Trudel et al, 1989Trudel et al, 1992Fedaku et al, 1992Jones et al, 1988Merza et al, 1991Osterhaus et al, 1992Takehashi et al, 1990Pyle et al, 1989Nagy et al, 1990Winter et al, 1988…”

mentioning

confidence: 99%

See 1 more Smart Citation

The iscom structure as an immune-enhancing moiety: experience with viral systems

Claassen

Osterhaus

1992

Research in Immunology

View full text Add to dashboard Cite

Section: Retroviridaementioning

confidence: 94%

mentioning

confidence: 99%

The iscom structure as an immune-enhancing moiety: experience with viral systems

Claassen

Osterhaus

1992

Research in Immunology

View full text Add to dashboard Cite

“…Immune response to HIV-gp 120 when delivered in ISCOMs showed the induction of ten folds higher antibody titers than gp 120 emulsified in depot adjuvant in rhesus monkeys with, generation of potent virus precipitating and neutralizing response to RF and MN isolates (36). Moreover the antisera from ISCOM immunized rhesus monkeys recognized gp 120 in the membranes of HIV-1 infected H9 cells, indicating the preservation of epitope structure in the ISCOM matrix.…”

Section: Iscomsmentioning

confidence: 97%

New age adjuvants and delivery systems for subunit vaccines

Koduri

Manocha

Sabhnani

et al. 2000

Indian J Clin Biochem

View full text Add to dashboard Cite

The dramatic advancements in the field of vaccinology has led to the formulation of chemically well defined vaccines composed of synthetic peptides and recombinant proteins derived from the immunologically dominant regions of the pathogens. Though these subunit vaccines are safer compared to the traditional vaccines they are known to be poorly immunogenic. This necessitates the use of adjuvants to enhance the immunogenicity of these vaccine formulations. The most common adjuvant for human use is alum. Research in the past has focused on the development of systemic immunity using conventional immunization protocols. In the present era, the emphasis is on the development and formulation of alternative adjuvants and delivery systems in generating systemic as well as mucosal immunity. This review mainly focuses on a variety of adjuvants (particulate as well as non-particulate) used with protective antigens of HIV, malaria, plague, leprosy using modified delivery vehicles. The experience of our laboratory and other researchers in this field clearly proves that these new age adjuvants and delivery systems undoubtedly generate enhanced immune response -both humoral and cell mediated. The choice of antigens, the nature of adjuvant used and the mode of delivery employed have a profound effect on the type of immune response generated. Besides the quantity, the quality of the antibodies generated also play a vital role in protection against these diseases. Some of the adjuvants and delivery systems used promoted high titre and affinity antibodies, which were shown to be cytophilic in nature, an important criteria in providing protection to the host. Thus the studies on these adjuvants/ delivery systems with respect to various infectious diseases indicate their active role in efficient modulation of immune response along with safety and permissiblity.

show abstract

“…Although it is possible to insert or at least associate non-amphipathic molecules with ISCOMs, structural modifications such as partial denaturation of proteins with urea and mercaptoethanol [33], exposure to low pH [34][35][36], or high temperature [31] were required to expose normally internal hydrophobic regions within proteins. Exposure to pH 2.5 buffers permitted 15 and 14% incorporation of purified HIV-1 gp120 [34] and bovine serum albumin (BSA) [35], respectively, into ISCOMs, whereas treatment of ovalbumin (OVA) [36] or BSA [31] at 70°C increased the incorporation level.…”

Section: Protein Association With Iscoms and Iscom Matrixmentioning

confidence: 99%

“…Exposure to pH 2.5 buffers permitted 15 and 14% incorporation of purified HIV-1 gp120 [34] and bovine serum albumin (BSA) [35], respectively, into ISCOMs, whereas treatment of ovalbumin (OVA) [36] or BSA [31] at 70°C increased the incorporation level. These methods may lead to a loss of conformationally dependent B cell epitopes.…”

Section: Protein Association With Iscoms and Iscom Matrixmentioning

confidence: 99%